Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
No phase specifiedTissue collection/RepositoryActiveNot specifiedNCI, OtherCDR0000357586
ECOG-E3903, E3903, NCT00897767

Trial Description

Summary

RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about diagnosing cancer and determine a patient's eligibility for a treatment clinical trial. It may also help the study of cancer in the future.

PURPOSE: This laboratory study is collecting tissue samples from patients with leukemia or other blood disorders who are planning to enroll in an ECOG leukemia treatment clinical trial.

Further Study Information

OBJECTIVES:

  • To provide a mechanism for sample collection and submission for diagnostic review to determine eligibility of patients with suspected leukemia or related hematologic disorders for enrollment on ECOG leukemia clinical trials.
  • To obtain baseline samples for correlative studies outlined in parent clinical trials.

OUTLINE: This is a cohort, multicenter study.

Patients submit bone marrow and/or blood samples. The samples are studied to determine patients' eligibility for ECOG leukemia treatment clinical trials. Samples may be stored for future correlative studies related to ECOG treatment clinical trials.

Eligibility Criteria

DISEASE CHARACTERISTICS:

  • Candidate for enrollment on an ECOG treatment clinical trial for acute or chronic leukemia
  • Suspected clinical diagnosis and protocol ID number of the treatment clinical trial under consideration must be submitted to ECOG's Leukemia Translational Studies Laboratory to ensure that the required antibody panels are used and functional assays are performed
  • Chosen ECOG treatment clinical trial must be active and accruing
  • Patient must not have begun treatment on the ECOG treatment clinical trial
  • Patient may be concurrently enrolled on this laboratory study and a treatment clinical trial if immediate treatment is medically necessary
  • If subsequent diagnostic review alters the original diagnosis, the patient will be removed from the treatment clinical trial

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics

Trial Contact Information

Trial Lead Organizations/Sponsors

Eastern Cooperative Oncology Group

  • National Cancer Institute
Elisabeth Paietta, Study Chair

Trial Sites

U.S.A.

Illinois
Galesburg

Medical and Surgical Specialists, LLC

Nguyet A Le-Lindqwister
Ph: 800-793-2262

Skokie

Hematology/Oncology of the North Shore at Gross Point Medical Center

Elisabeth Paietta

Massachusetts
Boston

Eastern Cooperative Oncology Group

Elisabeth M Paietta
Ph: 718-904-2730

New York
Bronx

Albert Einstein Cancer Center at Albert Einstein College of Medicine

Elisabeth Paietta

Ohio
Canton

Aultman Cancer Center at Aultman Hospital

Elisabeth Paietta

South Dakota
Sioux Falls

Avera Cancer Institute

Addison R Tolentino
Ph: 800-657-4377
Email: Jan.Healy@avera.org

Wisconsin
Madison

Dean Hematology & Oncology Clinic

Amit Sanyal
Ph: 608-410-2700

Link to the current ClinicalTrials.gov record.
NLM Identifier NCT00897767
ClinicalTrials.gov processed this data on February 27, 2015

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.